SCHEMBL19040648

SCHEMBL19040648

C/C=c1/cccc/c1=C/NC

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL819351 0.81 TSHR (0.35) TSHR
SCHEMBL18387086 0.81 TSHR (0.35) TSHR
SCHEMBL24266440 0.78
Methane SCHEMBL27622905 0.78 TSHR (0.33) TSHR
Water SCHEMBL28283535 0.78 TSHR (0.33) TSHR
SCHEMBL24482676 0.73
SCHEMBL25464945 0.70
SCHEMBL23350320 0.69
SCHEMBL12993101 0.69
SCHEMBL26216969 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 US disclosed
US-11195638-B2 Resin composition, prepreg, resin sheet, metal foil-clad laminate, and printed circuit board MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2021-12-07 US disclosed
US-20210363175-A1 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE SAGE THERAPEUTICS, INC. 2021-11-25 US disclosed
US-20210100802-A1 HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS ACEA Therapeutics, Inc. (US) 2021-04-08 US disclosed
US-20200152349-A1 RESIN COMPOSITION, PREPREG, RESIN SHEET, METAL FOIL-CLAD LAMINATE, AND PRINTED CIRCUIT BOARD MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2020-05-14 US disclosed
US-10461258-B2 Compound IDEMITSU KOSAN CO., LTD. (JP) 2019-10-29 US disclosed
EP-3354640-A2 MIF INHIBITORS AND THEIR USES Innovimmune Biotherapeutics, Inc. (US) 2018-08-01 EP disclosed
EP-2696682-B1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS INC (US) 2018-03-21 EP disclosed
US-9745613-B2 Compounds, substrates and methods related to histone deacetylases THE BROAD INSTITUTE, INC. (US) 2017-08-29 US disclosed
US-20170186968-A1 NOVEL COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2017-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF TEAD1, TEAD2, TEAD3 TSHR 2741/4885
US-10461258-B2 Compound CYP19A1, CYP17A1, CYP51A1 TSHR 4566/4885
US-20210363175-A1 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE NR3C2, GRIN2B, HTR1B TSHR 754/4885
US-20210100802-A1 HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS ERBB2, EGFR, ERBB3 TSHR 3465/4885
US-20170186968-A1 NOVEL COMPOUND SREBF1, BRIX1, SREBF2 TSHR 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.